Skip to main content
Premium Trial:

Request an Annual Quote

CareDx Acquires App Developer Transplant Hero

NEW YORK – Transplant diagnostics company CareDx said on Tuesday that it has acquired New York-based Transplant Hero, the developer of a smartphone app that's aimed at supporting the needs of transplant patients.

Financial terms of the deal were not disclosed.

Transplant Hero's app helps transplant patients manage their medications through the use of alarms and interactive logging of medication, CareDx said. The app offers support to various types of organ recipients including kidney, heart, lung, liver, pancreas, and small bowel.

CareDx said that the acquisition of Transplant Hero builds on AlloCare, the company's comprehensive mobile health app for managing patients' day-to-day health before and after transplant. CareDx will add the Transplant Hero app to its digital portfolio, which includes a suite of cloud-based solutions and software for transplant centers and dialysis providers.

"Transplant Hero's easy-to-use interface and transplant focus allows us to expand into different organs," Reg Seeto, CareDx's president and CEO, said in a statement. "We will be able to leverage Transplant Hero's well-established social media presence to augment AlloCare which has been built around patients from kidney transplant centers."

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.